JP2004508066A - 一種の突然変異型のヒト組織型プラスミノゲン活性剤を発現する細胞株、構築方法及び発現蛋白の調剤方法 - Google Patents
一種の突然変異型のヒト組織型プラスミノゲン活性剤を発現する細胞株、構築方法及び発現蛋白の調剤方法 Download PDFInfo
- Publication number
- JP2004508066A JP2004508066A JP2002527274A JP2002527274A JP2004508066A JP 2004508066 A JP2004508066 A JP 2004508066A JP 2002527274 A JP2002527274 A JP 2002527274A JP 2002527274 A JP2002527274 A JP 2002527274A JP 2004508066 A JP2004508066 A JP 2004508066A
- Authority
- JP
- Japan
- Prior art keywords
- tpa
- tnk
- cell line
- plasminogen activator
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 25
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 title claims abstract description 10
- 238000010276 construction Methods 0.000 title claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 51
- 108010051181 TNK-tissue plasminogen activator Proteins 0.000 claims abstract description 45
- 210000000349 chromosome Anatomy 0.000 claims abstract description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 12
- 210000003917 human chromosome Anatomy 0.000 claims abstract description 4
- 230000035790 physiological processes and functions Effects 0.000 claims abstract description 4
- 210000001519 tissue Anatomy 0.000 claims abstract description 3
- 230000002596 correlated effect Effects 0.000 claims abstract 2
- 108020004414 DNA Proteins 0.000 claims description 20
- 238000007429 general method Methods 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 102000019400 Tissue-type plasminogen activator Human genes 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 6
- 102000007999 Nuclear Proteins Human genes 0.000 abstract 1
- 108010089610 Nuclear Proteins Proteins 0.000 abstract 1
- 239000012528 membrane Substances 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 101710101078 Proton-activated chloride channel Proteins 0.000 description 8
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 108091092584 GDNA Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 229920006345 thermoplastic polyamide Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000001938 Plasminogen Activators Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940127126 plasminogen activator Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 2
- 101000614095 Homo sapiens Proton-activated chloride channel Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108020001027 Ribosomal DNA Proteins 0.000 description 2
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010031891 KHRR 296-299 AAAA T103N Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003774 sarcomatosis Diseases 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 101150010939 tpa gene Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/025—Change of phase or condition
- G01N2291/0256—Adsorption, desorption, surface mass change, e.g. on biosensors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2000/000260 WO2002020802A1 (en) | 2000-09-04 | 2000-09-04 | A cell line expressing mutant human tissue-type plasminogen activator, constructing strategy and method of expressed protein preparation |
| PCT/CN2001/000127 WO2002022832A1 (en) | 2000-09-04 | 2001-02-16 | A cell line expressing mutated human tissue - type plasminogen activator, the constructing strategy thereof and method of preparing expressed protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508066A true JP2004508066A (ja) | 2004-03-18 |
| JP2004508066A5 JP2004508066A5 (enExample) | 2005-02-24 |
Family
ID=4574691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002527274A Pending JP2004508066A (ja) | 2000-09-04 | 2001-02-16 | 一種の突然変異型のヒト組織型プラスミノゲン活性剤を発現する細胞株、構築方法及び発現蛋白の調剤方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7632677B2 (enExample) |
| EP (1) | EP1323826A4 (enExample) |
| JP (1) | JP2004508066A (enExample) |
| CN (1) | CN1216149C (enExample) |
| AU (2) | AU2000268170A1 (enExample) |
| WO (2) | WO2002020802A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112111475B (zh) * | 2020-09-24 | 2021-07-20 | 江苏丰华生物制药有限公司 | 一种经上皮细胞转运能力增强的TNK-tPA融合蛋白及其应用 |
| CN112490602B (zh) * | 2020-10-19 | 2021-09-24 | 电子科技大学 | 一种基于多层结构的THz导波调控装置 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3613390C2 (de) | 1985-04-22 | 2001-10-11 | Genentech Inc | Einkettige Human-Gewebeplasminogen-Aktivator (t-PA)-Mutanten, kodierende DNA, Expressionsvektor, Mikroorganismus, Zellkultur und pharmazeutische Zusammensetzung |
| DE3684680D1 (de) * | 1985-12-23 | 1992-05-07 | Chiron Corp | Peptidplasminogenaktivatoren. |
| PT86162B (pt) * | 1986-11-21 | 1990-11-20 | Smithkline Beecham Corp | Expressao de proteina recombinante |
| EP0340573A3 (de) * | 1988-04-30 | 1990-05-30 | BASF Aktiengesellschaft | Neue Proteine, ihre Herstellung und Verwendung |
| DE3927865A1 (de) * | 1989-08-23 | 1991-02-28 | Boehringer Mannheim Gmbh | T-pa-mutante gk1l |
| US5223408A (en) * | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
| US5795737A (en) * | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| CN1113099C (zh) * | 1996-10-26 | 2003-07-02 | 湖南医科大学 | 用于基因治疗的新的载体 |
| AU2000258017A1 (en) * | 2000-07-17 | 2002-02-13 | Jiahui Xia | Human source gene leading sequence, gene vector and gene expression strategy |
| CN1148228C (zh) * | 2000-08-30 | 2004-05-05 | 夏家辉 | 治疗血友病b的基因药物及其制备方法 |
-
2000
- 2000-09-04 AU AU2000268170A patent/AU2000268170A1/en not_active Abandoned
- 2000-09-04 WO PCT/CN2000/000260 patent/WO2002020802A1/zh not_active Ceased
-
2001
- 2001-02-16 CN CN018151094AA patent/CN1216149C/zh not_active Expired - Fee Related
- 2001-02-16 US US10/363,408 patent/US7632677B2/en not_active Expired - Fee Related
- 2001-02-16 JP JP2002527274A patent/JP2004508066A/ja active Pending
- 2001-02-16 WO PCT/CN2001/000127 patent/WO2002022832A1/zh not_active Ceased
- 2001-02-16 AU AU2001235320A patent/AU2001235320A1/en not_active Abandoned
- 2001-02-16 EP EP01907318A patent/EP1323826A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN1468310A (zh) | 2004-01-14 |
| CN1216149C (zh) | 2005-08-24 |
| AU2000268170A1 (en) | 2002-03-22 |
| US20040077042A1 (en) | 2004-04-22 |
| WO2002020802A1 (en) | 2002-03-14 |
| EP1323826A4 (en) | 2004-06-16 |
| AU2001235320A1 (en) | 2002-03-26 |
| EP1323826A1 (en) | 2003-07-02 |
| US7632677B2 (en) | 2009-12-15 |
| WO2002022832A1 (en) | 2002-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1685251T3 (en) | Nucleic acid | |
| KR0159107B1 (ko) | 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포 | |
| RU2105812C1 (ru) | Полипептид, обладающий уратоксидазной активностью, фрагмент днк, обеспечивающий экспрессию полипептида с уратоксидазной активностью (варианты), вектор экспрессии, содержащий фрагмент днк, обеспечивающий экспрессию полипептида с уратоксидазной активностью (варианты), штамм, экспрессирующий полипептид, обладающий уратоксидазной активностью (варианты), способ получения полипептида, обладающего уратоксидазной активностью | |
| PT96041A (pt) | Processo para a obtencao de plaminogenio resistente a clivagem e de composicoes que o contem | |
| JP2004508066A (ja) | 一種の突然変異型のヒト組織型プラスミノゲン活性剤を発現する細胞株、構築方法及び発現蛋白の調剤方法 | |
| US7361639B2 (en) | Gene therapy agent for Haemophilia B and its preparation method | |
| CN118852413A (zh) | 一种重组ⅱ型胶原蛋白及其在凝血和组织再生中的应用 | |
| JP7171434B2 (ja) | 遺伝的改変酵母細胞と血栓特異的ストレプトキナーゼ製造改良プロセス | |
| JP4944349B2 (ja) | ヒト由来の遺伝子先導配列、遺伝子ベクター及びその発現方法 | |
| West et al. | Evidence that the intron open reading frame of the phage T4 td gene encodes a specific endonuclease | |
| KR20230125806A (ko) | 선천성 근이영양증의 치료를 위한 치료용 lama2 페이로드 | |
| KR20210086662A (ko) | Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도 | |
| JP2001504683A (ja) | 単球およびマクロファージにおける遺伝子発現 | |
| JP2557385B2 (ja) | ヒトプロテインｓ | |
| WO1994028151A1 (en) | Gene therapy for haemophilia | |
| WO2001090169A1 (fr) | Nouveau polypeptide, antigene nucleaire de proliferation cellulaire (pcna) 13, et polynucleotide codant ce polypeptide | |
| WO2025112773A1 (zh) | Fundc1基因的突变体、突变质粒及其构建方法和应用 | |
| WO2001087953A1 (en) | A novel polypeptide-homo galactokinase 11 and polynucleotide encoding said polypeptide | |
| JPH04108379A (ja) | 新規スーパーオキサイドディスムターゼ | |
| WO2001048000A1 (fr) | Nouveau polypeptide, fibronectine 10 de type ii, et polynucleotide codant pour ce polypeptide | |
| WO2002012296A1 (en) | A novel polypeptide-nadp dependent leukotriene b412-hydroxydehydrogenase-36 and the polynucleotide encoding said polypeptide | |
| WO2001096572A1 (en) | A novel polypeptide- multi-copper oxidase 12 and the polynucleotide encoding said polypeptide | |
| JPH0851980A (ja) | 合成遺伝子およびこれを用いた癌転移阻害活性を有するペプチドの製造方法 | |
| WO2001055424A1 (fr) | Nouveau polypeptide, proteine d'oxydoreduction 4fe-4s 9, et polynucleotide codant pour ce polypeptide | |
| WO2001049725A1 (en) | A novel polypeptide-sigma-54 factor 13 and the polynucleotide encoding said polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060814 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061109 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070126 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070409 |